Articles

  • Nov 10, 2024 | psucollegian.com | Kevin Cheng

    After a dominant win over Washington, Penn State quarterback Drew Allar speaks highly on tight end Tyler Warren’s playmaking ability and how the offense has been “moving and grooving” to confuse defenses. Warren talks about the importance of bouncing back and not letting the Ohio State loss bleed into the White Out game. Defensive end Abdul Carter finishes by touching on how the team tries to start fast, looking to build on that throughout the season.

  • Nov 4, 2024 | psucollegian.com | Kevin Cheng

    After Penn State fell to Ohio State 20-13, players react to the loss. Drew Allar talks about reflecting over the next hours, looking at the good and the bad from the game and moving forward towards the rest of the season. Additionally, Tyler Warren talks about what they have done well and how they will learn from this game. He also discusses the importance of moving on and touches on the play close to a big touchdown. Finally, Nicholas Singleton speaks on team community during this time.

  • Oct 30, 2024 | watoday.com.au | Kevin Cheng

  • Oct 30, 2024 | smh.com.au | Kevin Cheng

    A new wave of venues are serving dishes from nearly every part of China, including the provinces of Fujian, Shaanxi and Hunan. Here is our guide to the rise of regional Chinese food in Sydney. Kevin ChengOctober 31, 2024, register or subscribe to save recipes for later. You have reached your maximum number of saved items. Remove items from your saved list to add more. Save this article for laterAdd articles to your saved list and come back to them anytime.

  • Jul 12, 2024 | radcliffecardiology.com | Vlado Perkovic |Kevin Cheng |Jonathan Hill |Pam R Taub

    ADA 24 - In this succinct video, we are joined by Dr Vlado Perkovic (UNSW Sydney, Kensington, AU) to discuss a trial investigating the use of semaglutide in patients with type 2 diabetes and chronic kidney disease (NCT03819153). The FLOW trial enrolled 3533 participants with type 2 diabetes and chronic kidney disease, who were then randomized to recieve either semaglutide or placebo. The median follow-up period was 3.4 years, as the trial was stopped early at a prespecified interim analysis.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →